

## Syros announces new data from Phase 2 Trial of Tamibarotene (TM-411/SY-1425) in combination with Azacitidine.

October 28, 2019---Syros Pharmaceuticals Inc. (Cambridge, Massachusetts, U.S. hereinafter referred to as "Syros") announced new data from Phase 2 combined clinical study on retinoic acid receptor alpha agonist (hereinafter referred to as "Tamibarotene") at the European School of Haematology (ESH) 5th International Conference Acute Myeloid Leukemia currently being held in Estoril, Portugal.

Tamibarotene is a drug licensed to Syros by our consolidated subsidiary TMRC Corporation ("TMRC").

In Sep. 2015, TMRC entered into a licensing agreement with Syros regarding the rights to develop and market Tamibarotene as a cancer treatment in North America and Europe. In addition to receiving an upfront payment, TMRC has the right to receive milestone payments according to the development stage and post-launch royalties.

Our group will further strengthen our alliance with Syros, strive to provide the necessary support without delay, and aim for early receipt of milestone income and royalty income in the future.

In detail clinical activity data, safety data and about Syros, please visit following Syros News Release.

<https://ir.syros.com/press-releases/detail/171/syros-announces-new-data-from-phase-2-trial-of-sy-1425-in>

End